Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice.

Background: The interest of first- and second-line treatments in non-small cell lung cancer (NSCLC) has been demonstrated by successive randomized trials. Improvements in lung cancer care have routinely allowed a significant proportion of patients to be considered for third-line treatment.

Methods: A retrospective analysis was performed, including all consecutive patients with advanced NSCLC, who received at least three lines of systemic antineoplastic treatment at our institution.

Twelve-year longitudinal study of respiratory status in dairy farmers.

To evaluate respiratory risk in dairy farmers, the present authors conducted a longitudinal study in the Doubs region of France. From a cohort constituted in 1986 (T1), 157 (62.8%) dairy farmers and 159 (63.

[Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].

Epidermal Growth Factor receptor (EGFR) are a key factor for the tumoral proliferation and its tumoral over expression appears to be a powerful prognosis factor. Currently, 2 types of treatments are targeting EGFR: a monoclonal antibodies anti-EGFR and a specific inhibitors of the EGFR tyrosine kinase. The administration of these compound alone or in combination with chemotherapy gives some promising results.

[Chemotherapy for patients with local-regional recurrent or metastatic carcinoma of the head and neck].

Chemotherapy has emerged to be a central component of curative strategies for patient with primary squamous cell carcinoma of the head and neck. The identification of agent active in head and neck cancer first occurred in patients with local regional recurrent and/or metastatic disease treated with palliative intent. The present paper reports the prognostic factors which based the understanding of these patients outcome.

Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors.

A multi-centre retrospective study involving 4 French university institutions has been conducted in order to identify routine pre-therapeutic prognostic factors of survival in patients with previously untreated non-small cell lung cancer and brain metastases at the time of presentation. A total of 231 patients were recorded regarding their clinical, radiological and biological characteristics at presentation. The accrual period was January 1991 to December 1998.